Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma

Exclusion Criteria

• •Before or at the same time any second malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
• •Any factors that influence the usage of oral administration
• •Known Spinal Cord compression or diseases of brain or pia mater by CT /MRI Screening
• •Imageology shows that tumor lesion less than 5 mm to great vessels(internal carotid and jugular vein)
• •Hemoglobin \< 90g/L, platelets \< 100×10\^9/L, neutrophils \< 2×10\^9/L, total bilirubin ≥ 1.25×the upper limit of normal(ULN), ALT\\AST ≥ 1.5x ULN), serum creatine \> 1x ULN, creatinine clearance rate \< 60ml/min, Cholesterol \> 7.75 mmol/L and triglyceride \> 3 mmol/L, LVEF: \< LLN
• •Hypertensive( more than 140/90 mmHg ), more than class I (NCI CTCAE 3.0 ) myocardial ischemia, arrhythmia(including QTcF:male ≥ 450 ms, female ≥470 ms), or cardiac insufficiency
• •URT: urine protein ≥ ++ and \> 1.0 g of 24 h
• •Long-term untreated wounds or fractures
• •PT, APTT, TT, Fbg abnormal, having hemorrhagic tendency (eg. active peptic ulcer disease) or receiving the therapy of thrombolysis or anticoagulation
• •Before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc
• •Preexisting thyroid dysfunction, even using medical therapy, thyroid function cannot maintain in the normal range
• •Abuse of Psychiatric drugs or dysphrenia
• •Subject of Viral hepatitis type B or type C
• •Subject of immunodeficiency: HIV positive, or other acquired immunodeficiency, congenital immunodeficiency, or organ transplantation
• •With drug CYP3A4 inhibitor, inducer, or substrate
• •Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study